Search Results - "Kozuki, Toshiyuki"

Skin problems and EGFR-tyrosine kinase inhibitor by Kozuki, Toshiyuki

Get full text

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial by Hida, Toyoaki, MD, Nokihara, Hiroshi, MD, Kondo, Masashi, MD, Kim, Young Hak, MD, Azuma, Koichi, MD, Seto, Takashi, MD, Takiguchi, Yuichi, Prof, Nishio, Makoto, MD, Yoshioka, Hiroshige, MD, Imamura, Fumio, MD, Hotta, Katsuyuki, Prof, Watanabe, Satoshi, MD, Goto, Koichi, MD, Satouchi, Miyako, MD, Kozuki, Toshiyuki, MD, Shukuya, Takehito, MD, Nakagawa, Kazuhiko, Prof, Mitsudomi, Tetsuya, Prof, Yamamoto, Nobuyuki, Prof, Asakawa, Takashi, PhD, Asabe, Ryoichi, MS, Tanaka, Tomohiro, MS, Tamura, Tomohide, Dr

“…Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability…”
Get full text

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study by Katsuya, Yuki, Horinouchi, Hidehito, Seto, Takashi, Umemura, Shigeki, Hosomi, Yukio, Satouchi, Miyako, Nishio, Makoto, Kozuki, Toshiyuki, Hida, Toyoaki, Sukigara, Tamie, Nakamura, Kenichi, Kuchiba, Aya, Ohe, Yuichiro

“…Thymic carcinoma (TC) is a rare cancer with a poor prognosis and limited treatment options, especially after relapse. In this open-label, two-stage,…”
Get full text

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer by Hotta, Katsuyuki, Aoe, Keisuke, Kozuki, Toshiyuki, Ohashi, Kadoaki, Ninomiya, Kiichiro, Ichihara, Eiki, Kubo, Toshio, Ninomiya, Takashi, Chikamori, Kenichi, Harada, Daijiro, Nogami, Naoyuki, Hirata, Taizo, Hinotsu, Shiro, Toyooka, Shinichi, Kiura, Katsuyuki

“…Trastuzumab emtansine (T-DM1), an anti-erb-b2 receptor tyrosine kinase 2 (HER2) antibody-drug conjugate, has been shown to significantly improve survival in…”
Get more information

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer by Nakagawa, Kazuhiko, Hida, Toyoaki, Nokihara, Hiroshi, Morise, Masahiro, Azuma, Koichi, Kim, Young Hak, Seto, Takashi, Takiguchi, Yuichi, Nishio, Makoto, Yoshioka, Hiroshige, Kumagai, Toru, Hotta, Katsuyuki, Watanabe, Satoshi, Goto, Koichi, Satouchi, Miyako, Kozuki, Toshiyuki, Koyama, Ryo, Mitsudomi, Tetsuya, Yamamoto, Nobuyuki, Asakawa, Takashi, Hayashi, Morihiko, Hasegawa, Wakako, Tamura, Tomohide

“…•Final PFS data and second pre-planned interim analysis of OS and safety from J-ALEX.•Sustained improvement in IRF-assessed PFS demonstrated with…”
Get full text

Impact of neutrophil-to-lymphocyte ratio throughout the course of chemoradiotherapy on overall survival and distant failure in unresectable stage III non-small cell lung cancer by Kanzaki, Hiromitsu, Hamamoto, Yasushi, Nagasaki, Kei, Kozuki, Toshiyuki

“…Purpose Neutrophil-to-lymphocyte ratio (NLR) has been reported to be associated with treatment outcomes in various cancers; however, the optimal timing to…”
Get full text

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial by Goto, Koichi, Dr, Ohe, Yuichiro, MD, Shibata, Taro, MSc, Seto, Takashi, MD, Takahashi, Toshiaki, MD, Nakagawa, Kazuhiko, Prof, Tanaka, Hiroshi, MD, Takeda, Koji, MD, Nishio, Makoto, MD, Mori, Kiyoshi, MD, Satouchi, Miyako, MD, Hida, Toyoaki, MD, Yoshimura, Naruo, MD, Kozuki, Toshiyuki, MD, Imamura, Fumio, MD, Kiura, Katsuyuki, Prof, Okamoto, Hiroaki, MD, Sawa, Toshiyuki, MD, Tamura, Tomohide, MD

“…Summary Background Etoposide and irinotecan are key drugs in the treatment of small-cell lung cancer. We did this study to investigate whether combined…”
Get full text

Nivolumab for the treatment of unresectable pleural mesothelioma by Hotta, Katsuyuki, Fujimoto, Nobukazu, Kozuki, Toshiyuki, Aoe, Keisuke, Kiura, Katsuyuki

“…: Platinum-based chemotherapy is the current first-line standard therapy for unresectable malignant pleural mesothelioma (MPM). Recently, immune-checkpoint…”
Get more information

Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors by Fujiwara, Yutaka, Iguchi, Haruo, Yamamoto, Noboru, Hayama, Manabu, Nii, Masahiro, Ueda, Shinya, Komuro, Keiko, Sugimoto, Mariko, Vlahovic, Gordana, Kozuki, Toshiyuki

“…Blockade of programmed cell death ligand‐1 with durvalumab has shown efficacy and safety in large, international studies of patients with advanced solid…”
Get full text

An easy tool to predict survival in patients with bone metastatic lung cancer treated with palliative radiotherapy by Makita, Kenji, Hamamoto, Yasushi, Kanzaki, Hiromitsu, Nagasaki, Kei, Kozuki, Toshiyuki

“…Background This study aimed to devise a simple assessment system for bone metastases (BMs) from lung cancer (LC). Methods A total of 368 LC patients with BMs…”
Get full text

A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401 by Ninomiya, Kiichiro, Yokoyama, Toshihide, Hotta, Katsuyuki, Oze, Isao, Katsui, Kuniaki, Hata, Tae, Yoshioka, Hiroshige, Bessho, Akihiro, Hosokawa, Shinobu, Kuyama, Shoichi, Kudo, Kenichiro, Kozuki, Toshiyuki, Harada, Daijiro, Yasugi, Masayuki, Murakami, Toshi, Nakanishi, Masamoto, Takigawa, Nagio, Maeda, Yoshinobu, Kiura, Katsuyuki

“…Background Radiation esophagitis is a critical adverse event that needs to be appropriately managed while administering thoracic irradiation. This trial aimed…”
Get full text

Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy by Harada, Daijiro, Takata, Kenji, Mori, Shunta, Kozuki, Toshiyuki, Takechi, Yoshika, Moriki, Satoko, Asakura, Yumi, Ohno, Takayuki, Nogami, Naoyuki

“…For immune checkpoint inhibitor (ICI)-pretreated patients, docetaxel and ramucirumab (DOC+RAM) combination therapy may be more effective compared to patients…”
Get full text

Clinical features and treatment of epidermal growth factor inhibitor‐related late‐phase papulopustular rash by Tohyama, Mikiko, Hamada, Makoto, Harada, Daijiro, Kozuki, Toshiyuki, Nogami, Naoyuki, Monden, Nobuya, Kajiwara, Takeshi, Nishina, Tomohiro

“…Papulopustular rash, an acneiform rash, appears on the seborrheic region during the first to second week of treatment with an epidermal growth factor receptor…”
Get full text

Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS) by Katakami, Nobuyuki, Yokoyama, Toshihide, Morita, Satoshi, Okamoto, Tatsuro, Urata, Yoshiko, Hattori, Yoshihiro, Iwamoto, Yasuo, Sato, Yuki, Ikeda, Norihiko, Takahashi, Toshiaki, Daga, Haruko, Oguri, Tetsuya, Fujisaka, Yasuhito, Nishino, Kazumi, Sugawara, Shunichi, Kozuki, Toshiyuki, Oki, Masahide, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko

“…Background Since the overall survival (OS) of patients enrolled in the first clinical phase III trial (WJOG5108L) was not recorded owing to time constraints,…”
Get full text

Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non-small cell lung cancer cell line by OGINO, Atsuko, KITAO, Hiroyuki, HIRANO, Seiki, UCHIDA, Akiko, ISHIAI, Masamichi, KOZUKI, Toshiyuki, TAKIGAWA, Nagio, TAKATA, Minoru, KIURA, Katsuyuki, TANIMOTO, Mitsune

“…The epidermal growth factor receptor (EGFR)-specific tyrosine kinase inhibitor gefitinib may provide dramatic clinical responses in some patients with…”
Get full text

Association between tumor cell in air space and treatment outcomes in early-stage lung cancer treated with stereotactic body radiation therapy by Makita, Kenji, Hamamoto, Yasushi, Kanzaki, Hiromitsu, Nagasaki, Kei, Matsuki, Hirokazu, Inoue, Koji, Kozuki, Toshiyuki

“…•Pretreatment TCIAS status correlated with RFF, DFF, and PFS after SBRT in early-stage lung cancer.•TCIAS-positive is an unfavorable factor for failure after…”
Get full text

Handling of Germline Findings in Clinical Comprehensive Cancer Genomic Profiling by Okazawa-Sakai, Mika, Yamamoto, Yasuko, Futagawa, Mashu, Okamura, Miki, Miyawaki, Satoko, Nishina, Tomohiro, Takehara, Kazuhiro, Kozuki, Toshiyuki, Tomida, Shuta, Hyodo, Ichinosuke, Ohsumi, Shozo, Hirasawa, Akira

“…Patients found to have presumed germline pathogenic variants (PGPVs) during comprehensive genomic profiling (CGP) require genetic counseling (GC) referrals. We…”
Get full text

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study by Sakai, Hiroshi, Morise, Masahiro, Kato, Terufumi, Matsumoto, Shingo, Sakamoto, Tomohiro, Kumagai, Toru, Tokito, Takaaki, Atagi, Shinji, Kozuki, Toshiyuki, Tanaka, Hiroshi, Chikamori, Kenichi, Shinagawa, Naofumi, Takeoka, Hiroaki, Bruns, Rolf, Straub, Josef, Schumacher, Karl Maria, Paik, Paul K

“…Abstract Background MET exon 14 skipping is an oncogenic driver occurring in 3–4% of non-small cell lung cancer (NSCLC). The MET inhibitor tepotinib has…”
Get full text

Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005) by Kanaji, Nobuhiro, Ichihara, Eiki, Tanaka, Takaaki, Ninomiya, Takashi, Kozuki, Toshiyuki, Ishikawa, Nobuhisa, Nishii, Kazuya, Shoda, Hiroyasu, Yamaguchi, Kakuhiro, Kawakado, Keita, Toyoda, Yuko, Inoue, Masaaki, Miyatake, Nobuyuki, Watanabe, Naoki, Inoue, Takuya, Mizoguchi, Hitoshi, Komori, Yuta, Kojima, Kazuki, Kadowaki, Norimitsu

“…Purpose This study investigated the safety and efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) re-administration after…”
Get full text

Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801 by Hosokawa, Shinobu, Ichihara, Eiki, Harada, Daijiro, Kuyama, Shoichi, Inoue, Koji, Gemba, Kenichi, Ichikawa, Hirohisa, Kato, Yuka, Oda, Naohiro, Oze, Isao, Tamura, Tomoki, Kozuki, Toshiyuki, Umeno, Takahiro, Kubo, Toshio, Hotta, Katsuyuki, Bessho, Akihiro, Maeda, Yoshinobu, Kiura, Katsuyuki

“…Background The role of pembrolizumab in the treatment of poor performance status (PS) patients remains unclear. Patients and methods We conducted a phase II…”
Get full text